ADC Therapeutics SA (ADCT)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADC Therapeutics SA (“ADC” or “the Company”) (NYSE: ADCT). Investors who purchased ADC shares are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether ADC has violated federal securities laws.

On September 9, 2022, ADC was subject to a Morgan Stanley downgrade from “overweight” to “equal weight.” Analysts cited concerns about its Zynlonta product’s market penetration. Following this news, ADC dropped over 5% that same day.

If you are aware of any facts relating to this investigation or purchased ADC shares you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.  The firm has recovered hundreds of millions of dollars for investors nationwide.  Attorney advertising. Prior results do not guarantee similar outcomes.